Augmentation Strategies for Inadequate Response to Fluoxetine

First-Line Augmentation Options

The American College of Cardiology is not relevant here, however, the most effective augmentation strategy for patients with inadequate response to fluoxetine is adding an atypical antipsychotic, particularly risperidone or aripiprazole, which have the strongest evidence for efficacy 1, 2, 3
Risperidone and aripiprazole have the strongest evidence for efficacy in augmenting fluoxetine in treatment-resistant depression 2, 3
Approximately one-third of patients with SSRI-resistant depression show clinically meaningful response to antipsychotic augmentation 3
Careful monitoring for adverse effects is essential, particularly weight gain and metabolic dysregulation 3
Fluoxetine plus clomipramine has been shown to significantly reduce symptoms in SSRI-resistant patients 2, 3
This combination was superior to fluoxetine plus quetiapine in a randomized controlled trial 3
Important caution: This combination increases the risk of severe adverse events including seizures, cardiac arrhythmias, and serotonin syndrome due to increased blood levels of both medications 2, 3
Close monitoring of drug levels is essential if using this combination 3
Lithium can be used to augment fluoxetine at doses of 150-300 mg/day, with target blood levels of 0.2-0.6 mEq/L 4, 5
Lithium is particularly useful for patients with bipolar features or cyclical mood patterns 5
Monitor for neurotoxicity, especially in elderly patients 5

N-acetylcysteine has the strongest evidence among glutamatergic agents, with three out of five randomized controlled trials showing superiority to placebo 2, 6
Memantine has also demonstrated efficacy in several trials and can be considered in clinical practice 6
Other options with some evidence include lamotrigine, topiramate, and riluzole 6
Adding Cognitive Behavioral Therapy (CBT) to fluoxetine has shown larger effect sizes compared to augmentation with risperidone 2
CBT should be considered when available and when the patient can engage with therapy 2
CBT is particularly effective for patients with comorbid anxiety disorders 1

Consider increasing fluoxetine to maximum recommended dose before augmentation 2
Higher doses are associated with greater efficacy but also higher dropout rates due to side effects 7
Switching to a different SSRI or an SNRI is a valid strategy for inadequate response 2, 3

Fluoxetine inhibits CYP2D6, potentially increasing blood levels of concomitant medications 7
CYP2D6 poor metabolizers may have 3.9-11.5 fold higher fluoxetine levels, requiring dose adjustment before considering augmentation 7
Monitor for QT prolongation when combining medications, especially in patients with risk factors 7
When combining with clomipramine, start with very low doses of clomipramine and monitor blood levels closely 3

Deep repetitive transcranial magnetic stimulation (rTMS) has FDA approval for treatment-resistant depression 6
Electroconvulsive therapy may be required in patients who are severely ill and do not respond to pharmacological augmentation strategies 4